Scientific Program

Scientific Program

View the MDS 2020 scientific program by clicking the button below!

Various topics on all relevant aspects of MDS will be covered, including (molecular) genetics, epidemiology, pathogenesis, diagnostics, co-morbidities, follow-up methods and finally, current and future treatment strategies. Through the collaboration of both international and local scientific committees, we are preparing an excellent scientific program that combines educational sessions with cutting edge updates and the results of recent basic and clinical research. Real-world patient discussions will also be part of the program.

Note: there is no Abstract Submission for the MDS 2020 Regional Symposium 

Scientific Program
*The program is updated as of 19 February 2020 and is subject to change.

Thursday, 5 March 2020

08:00-08:30 Registration & Gathering

Opening Ceremony

08:30-08:40: Welcome Greetings Moshe Mittelman (Israel); Stephen Nimer (USA)

08:40-08:50: The History of MDS Moshe Mittelman (Israel)

Session 1: Genetics, Biology and Epidemiology
Chairs: Galia Stemer (Israel); David Steensma (USA)

08:50-09:10: Genetics of MDS Rafael Bejar (USA)

09:10-09:30: MDS and Clonal Hematopoiesis David Steensma (USA)

09:30-09:50: ICUS and CCUS: non-MDS, pre-MDS or early MDS? Luca Malcovati (Italy)

09:50-10:00: Etiology and Epidemiology Drorit Merkel (Israel)

10:00-10:20: The Role of Stem Cells Ghulam Mufti (UK)

10:20-11:00 Coffee Break & Visit Exhibition

Session 2: Pathogenesis and Diagnosis
Chairs: Kalman Filanovsky (Israel); Theo de Witte (The Netherlands)

11:00-11:20: Innate Immunity in MDS Pathogenesis Alan List (USA)

11:20-11:40: AML post MDS Yishai Ofran (Israel) Supported by AbbVie

11:40-12:00: Lessons from the EUMDS Registry Theo de Witte (The Netherlands)

MDS – Non-Routine Diagnosis:

12:00-12:10: MicroRNA Signature in Myelodysplastic Syndrome Inga Mandac (Croatia)

12:10-12:20: Can We Diagnose MDS Without a BM Examination? Howard S. Oster (Israel)

12:20-13:00: Patient Discussion 1
Panel: Alan List (USA); Yishai Ofran (Israel); Ghulam Mufti (UK); Rafael Bejar (USA)
Presenters: Marin Ellis (Israel); Drorit Merkel (Israel); Merav Barzilai (Israel)

13:00-13:30 Lunch Break & Visit Exhibition

Satellite symposium supported by Novartis: Iron chelation and targeted therapy in MDS: Shifting the treatment paradigm

13:30-13:45 Welcome and Introductions Moshe Mittelman – Chair (Israel)
Are current therapies doing enough to meet the needs of patients with MDS? Panel discussion

13:45-14:00 Rethinking treatment selection for patients with low-risk MDS Emanuele Angelucci (Italy)

14:00-14:15 Moving towards a targeted approach for patients with MDS Uwe Platzbecker (Germany)

14:15-14:30 Paving the way for novel therapeutic opportunities in MDS Q&A and Panel discussion
Meeting close Moshe Mittelman (Israel)

Session 3: Clinical MDS (I) Supported by Fibrogen and Neopharm Israel
Chairs: Hanna Tamari (Israel); Peter Greenberg (USA)

14:30-14:50: Genetic Predisposition to MDS Akiko Shimamura (USA)

14:50-15:10: Molecular and Clinical Classifications of MDS Peter Greenberg (USA)

15:10-15:30: Splicing Factor Mutant Myelodysplastic Syndromes Luca Malcovati (Italy)

15:30-15:50: Precision Medicine in 2020 Stephen Nimer (USA)

15:50-16:30 Coffee Break & Visit Exhibition

Session 4: Clinical MDS (II)
Chairs: Maya Koren-Michowitz (Israel); Rena Buckstein (Canada)

16:30-16:50: The Impact of Comorbidities and Infections in the Course and Prognosis of MDS Argiris Symeonidis (Greece)

16:50-17:10: Optimizing Transfusion Support in MDS. Is What We Are Doing What Patients Want? Rena Buckstein (Canada)

17:10-18:00: Patient Discussion 2
Panel: Akiko Shimamura (USA); Peter Greenberg (USA); Argiris Symeonidis (Greece); Rena Buckstein (Canada)
Presenters: Maya Zlotnick (Israel); Mika Geva (Israel); Efrat Yaara ArzyHabar (Israel)

Satellite symposium supported by Celgene. A Bristol-Myers Squibb Company: Ineffective erythropoiesis in MDS: Targets for treatment in the new decade

18:00 – 18:05 Welcome and introduction Moshe Mittelman – Chair (Israel)

18:05 – 18:25 Ineffective erythropoiesis in MDS – what do we know? Moshe Mittelman (Israel)

18:25 – 18:55 Novel treatment targets: investigating key players in the regulation of erythropoiesis Valeria Santini (Italy)

18:55 – 19:00 Closing remarks Moshe Mittelman (Israel)

19:00 – 20:00 Evening Reception supported by BMS (Exhibition)

Friday, 6 March 2020

Session 5: Treatment of MDS (I) Supported by Gamida Cell Boston
Chairs: Ilana Hellman (Israel); Valeria Santini (Italy)

08:30-09:00: Treatment of Anemia and Thrombocytopenia Uwe Platzbecker (Germany)

09:00-09:20: Lenalidomide and Immune Suppressive Treatment Valeria Santini (Italy)

09:20-09:40: Stem Cell Transplant Theo de Witte (The Netherlands)

09:40-10:30: Patient Discussion 3
Panel: Uwe Platzbecker (Germany); Valeria Santini (Italy); Theo de Witte (The Netherlands); Jacob Rowe (Israel)
Presenters: Nicolas Bonadies (Switzerland); Galia Stemer (Israel); May Basood (Israel)

10:30-11:00 Coffee Break & Visit Exhibition

Session 6: Treatment of MDS (II) Supported by Takeda Oncology
Chairs: Yishai Ofran (Israel); Pierre Fenaux (France)

11:00-11:20: Hypomethylating Agents Pierre Fenaux (France)

11:20-11:40: Beyond HMA (I) – Combinations of Drugs Mikkael Sekeres (USA)

11:40-12:00: Beyond HMA (II) – Novel Agents Lewis Silverman (USA)

12:00-12:20: What is in the pipeline? Guillermo Garcia-Manero (USA)

12:20-13:00: Patient discussion 4
Panel: Mikkael Sekeres (USA); Lewis Silverman (USA); Guillermo Garcia-Manero (USA); Ofir Wallach (Israel)
Presenters: Rotem keidar (Israel); Kalman Filanovski (Israel); Moshe Mittelman (Israel)

13:00-13:10 Farewell:

Closing Remarks Drorit Merkel (Israel); Stephen Nimer (USA)

2nd Latin American MDS Symposium 2020 in Uruguay Marcelo Iastrebner (Uruguay)

MDS 2021, Toronto Rena Buckstein (Canada)